Prescient Therapeutics tops-up cash reserves to progress innovative cancer therapies

Prescient Therapeutics (ASX: PTX) managing director and chief executive officer Steven Yatomi-Clarke joins Small Caps to discuss the company’s plans for its innovative cancer therapies PTX-100 and PTX-200.

Prescient launched an $8 million capital raising last month to fund the progression of the two therapies towards first in-human clinical studies.

The company is also advancing its next generation OmniCAR CAR-T platform for fighting cancer, which it says can do what conventional CAR-T cannot.

Articles:
https://smallcaps.com.au/prescient-therapeutics-enters-strategic-collaboration-renowned-cancer-centre-us/
https://smallcaps.com.au/prescient-therapeutics-progress-innovative-pipeline-cancer-treatments-capital-raise/
https://smallcaps.com.au/prescient-therapeutics-signs-deal-q-gen-omnicar-clinical-trials/

For more information on Prescient Therapeutics:
https://smallcaps.com.au/stocks/PTX/

-----------------------

Small Caps is Australia's #1 site for market news & information on ASX listed small cap companies.

-----------------------

WEBSITE
https://smallcaps.com.au/

PODCAST
https://smallcaps.com.au/podcast/

SOCIAL MEDIA
Facebook: https://www.facebook.com/SmallCapsASX
Twitter: https://twitter.com/SmallCapsASX
LinkedIn: https://www.linkedin.com/company/small-caps/

NEWSLETTER
https://smallcaps.com.au/subscribe/